{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:05:52Z","timestamp":1787025952523,"version":"build-2736575974"},"reference-count":254,"publisher":"Tech Science Press","issue":"10","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["OR"],"published-print":{"date-parts":[[2025]]},"DOI":"10.32604\/or.2025.066260","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T09:00:41Z","timestamp":1756976441000},"page":"2603-2656","source":"Crossref","is-referenced-by-count":1,"title":["Pharmacological Phase I Clinical Trials in Pediatric Brain Tumors (1990\u20132024): A Historical Perspective"],"prefix":"10.32604","volume":"33","author":[{"given":"Rosa","family":"Scarpitta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emiliano","family":"Cappello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Cangialosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veronica","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia De","family":"Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Gori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guido","family":"Bocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"17807","published-online":{"date-parts":[[2025]]},"reference":[{"key":"ref1","unstructured":"National Cancer Institute. The surveillance, epidemiology, and end results program (SEER), cancer stat facts: childhood brain and other nervous system cancer. U.S. mortality 2019\u20132023, ages 0\u201319, age-adjusted rate. [cited 2025 Aug 4]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/childbrain.html."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/jmedgenet-2020-107627","article-title":"Diagnostic criteria for constitutional mismatch repair deficiency (CMMRD): recommendations from the international consensus working group","volume":"59","author":"Aronson","year":"2022","journal-title":"J Med Genet"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1158\/1078-0432.CCR-25-0423","article-title":"Pediatric cancer predisposition and surveillance update: summary perspective and future directions","volume":"31","author":"Brodeur","year":"2025","journal-title":"Clin Cancer Res"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1007\/s00401-016-1545-1","article-title":"The 2016 World Health Organization classification of tumors of the central nervous system: a summary","volume":"131","author":"Louis","year":"2016","journal-title":"Acta Neuropathol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/s41568-024-00684-9","article-title":"Developmental origins shape the paediatric cancer genome","volume":"24","author":"Chen","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"4324","DOI":"10.1038\/s41467-020-18070-y","article-title":"Pediatric pan-central nervous system tumor analysis of immune-cell infiltration identifies correlates of antitumor immunity","volume":"11","author":"Grabovska","year":"2020","journal-title":"Nat Commun"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/neuonc\/noab106","article-title":"The 2021 WHO classification of tumors of the central nervous system: a summary","volume":"23","author":"Louis","year":"2021","journal-title":"Neuro-Oncology"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00247-022-05546-w","article-title":"Changes to pediatric brain tumors in 2021 World Health Organization classification of tumors of the central nervous system","volume":"53","author":"Oztek","year":"2023","journal-title":"Pediatr Radiol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1922","DOI":"10.1056\/NEJMra2116344","article-title":"Brain tumors in children","volume":"386","author":"Cohen","year":"2022","journal-title":"N Engl J Med"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"982","DOI":"10.5306\/wjco.v15.i8.982","article-title":"Current challenges in the treatment of gliomas: the molecular era","volume":"15","author":"Fern\u00e1ndez","year":"2024","journal-title":"World J Clin Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"101942","DOI":"10.1016\/j.canep.2021.101942","article-title":"Epidemiology and prognostic factors of pediatric brain tumor survival in the US: evidence from four decades of population data","volume":"72","author":"Hossain","year":"2021","journal-title":"Cancer Epidemiol"},{"key":"ref12","first-page":"iv1","article-title":"CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016\u20132020","volume":"25","author":"Ostrom","year":"2023","journal-title":"Neurooncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s40478-020-00974-x","article-title":"The pediatric supratentorial MYCN-amplified high-grade gliomas methylation class presents the same radiological, histopathological and molecular features as their pontine counterparts","volume":"8","author":"Tauzi\u00e8de-Espariat","year":"2020","journal-title":"Acta Neuropathol Commun"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ncl.2018.04.009","article-title":"Pediatric brain tumors","volume":"36","author":"Udaka","year":"2018","journal-title":"Neurol Clin"},{"key":"ref15","first-page":"S33","article-title":"Circumscribed astrocytic gliomas: contribution of molecular analyses to histopathology diagnosis in the WHO CNS5 classification","volume":"65","author":"K\u00f6y","year":"2022","journal-title":"Indian J Pathol Microbiol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s00401-018-1837-8","article-title":"Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A\/B and ATRX alterations","volume":"136","author":"Reinhardt","year":"2018","journal-title":"Acta Neuropathol"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1617169","DOI":"10.3389\/fonc.2025.1617169","article-title":"Optimizing outcomes in intracranial ependymoma: a contemporary review","volume":"15","author":"Pan","year":"2025","journal-title":"Front Oncol"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1186\/s40478-018-0630-1","article-title":"Significance of molecular classification of ependymomas: c11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors","volume":"6","author":"Fukuoka","year":"2018","journal-title":"Acta Neuropathol Commun"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"2451","DOI":"10.1007\/s00381-021-05207-7","article-title":"Pediatric ependymoma: an overview of a complex disease","volume":"37","author":"J\u00fcnger","year":"2021","journal-title":"Child\u2019s Nerv Syst"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1227\/neu.0000000000002923","article-title":"Impact of molecular subgroups on prognosis and survival outcomes in posterior fossa ependymomas: a retrospective study of 412 cases","volume":"95","author":"Wang","year":"2024","journal-title":"Neurosurgery"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1007\/s11060-016-2135-8","article-title":"Spinal cord ependymoma: a review of the literature and case series of ten patients","volume":"128","author":"Celano","year":"2016","journal-title":"J Neuro Oncol"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11060-024-04623-4","article-title":"Clinical presentation and extent of resection impacts progression-free survival in spinal ependymomas","volume":"167","author":"Davison","year":"2024","journal-title":"J Neurooncol"},{"key":"ref23","first-page":"vdae179","article-title":"Impact of molecular classification on prognosis in children and adolescents with spinal ependymoma: results from the HIT-MED database","volume":"6","author":"Engertsberger","year":"2024","journal-title":"Neurooncol Adv"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.neuchi.2019.04.006","article-title":"Medulloblastoma: clinical presentation","volume":"67","author":"Vinchon","year":"2021","journal-title":"Neurochirurgie"},{"key":"ref25","first-page":"S73","article-title":"Embryonal tumors in the WHO CNS5 classification: a review","volume":"65","author":"Gianno","year":"2022","journal-title":"Indian J Pathol Microbiol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"101186","DOI":"10.1016\/j.spen.2025.101186","article-title":"Pediatric CNS tumors: overview and treatment paradigms","volume":"53","author":"Parikh","year":"2025","journal-title":"Semin Pediatr Neurol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"21075","DOI":"10.1002\/cam4.6647","article-title":"Chemotherapy in pediatric brain tumor and the challenge of the blood-brain barrier","volume":"12","author":"Malik","year":"2023","journal-title":"Cancer Med"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"101098","DOI":"10.1016\/j.neo.2024.101098","article-title":"Pediatric neuro-oncology: highlights of the last quarter-century","volume":"59","author":"Power","year":"2025","journal-title":"Neoplasia"},{"key":"ref29","first-page":"1","author":"Scholar","year":"2007","journal-title":"xPharm: the comprehensive pharmacology reference"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1159\/000073369","article-title":"Ifosfamide in pediatric solid tumors","volume":"65","author":"Carli","year":"2003","journal-title":"Oncology"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/FPC.0000000000000019","article-title":"PharmGKB summary: ifosfamide pathways, pharmacokinetics and pharmacodynamics","volume":"24","author":"Lowenberg","year":"2014","journal-title":"Pharmacogenet Genom"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s00467-004-1807-3","article-title":"Cytochrome P450 3A and 2B6 in the developing kidney: implications for ifosfamide nephrotoxicity","volume":"20","author":"Aleksa","year":"2005","journal-title":"Pediatr Nephrol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/pbc.10375","article-title":"Outcome of pediatric recurrent and refractory malignant solid tumors following ifosfamide\/carboplatin\/etoposide (ICE): a phase II study in a pediatric oncology centre in Brazil","volume":"42","author":"Loss","year":"2004","journal-title":"Pediatr Blood Cancer"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1445-5994.1998.tb01976.x","article-title":"The role of ifosfamide in paediatric cancer","volume":"28","author":"Advani","year":"1998","journal-title":"Aust N Z J Med"},{"key":"ref35","first-page":"537583","article-title":"Designing platinum compounds in cancer: structures and mechanisms","volume":"5","author":"Boulikas","year":"2007","journal-title":"Cancer Ther"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/CAD.0b013e3283650bda","article-title":"Platinum compounds in children with cancer","volume":"24","author":"Ruggiero","year":"2013","journal-title":"Anti Cancer Drugs"},{"key":"ref37","first-page":"309","volume":"5","author":"Baker","year":"1999","journal-title":"Clin Cancer Res"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/1874467211205010102","article-title":"Temozolomide: mechanisms of action, repair and resistance","volume":"5","author":"Zhang","year":"2012","journal-title":"Curr Mol Pharmacol"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"e0140131","DOI":"10.1371\/journal.pone.0140131","article-title":"Temozolomide resistance in glioblastoma cell lines: implication of MGMT, MMR, P-glycoprotein and CD133 expression","volume":"10","author":"Perazzoli","year":"2015","journal-title":"PLoS One"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3390\/jpm13060999","article-title":"MGMT promoter methylation: prognostication beyond treatment response","volume":"13","author":"Ashkan","year":"2023","journal-title":"J Pers Med"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1186\/s12885-016-2323-0","article-title":"Chemotherapy for intracranial ependymoma in adults","volume":"16","author":"Gramatzki","year":"2016","journal-title":"BMC Cancer"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/neuonc\/nov167","article-title":"Temozolomide as salvage treatment for recurrent intracranial ependymomas of the adult: a retrospective study","volume":"18","author":"Rud\u00e0","year":"2016","journal-title":"Neuro Oncol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1007\/s00401-015-1405-4","article-title":"Integrated analysis of pediatric glioblastoma reveals a subset of biologically favorable tumors with associated molecular prognostic markers","volume":"129","author":"Korshunov","year":"2015","journal-title":"Acta Neuropathol"},{"key":"ref44","first-page":"2350","article-title":"Camptothecin (CPT) and its derivatives are known to target topoisomerase I (Top1) as their mechanism of action: did we miss\n\nsomething in CPT analogue molecular targets for treating human disease such as cancer?","volume":"7","author":"Li","year":"2017","journal-title":"Am J Cancer Res"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"8955","DOI":"10.1021\/bi00085a029","article-title":"Specific interaction of camptothecin, a topoisomerase I inhibitor, with guanine residues of DNA detected by photoactivation at 365 nm","volume":"32","author":"Leteurtre","year":"1993","journal-title":"Biochemistry"},{"key":"ref46","first-page":"3301","article-title":"New molecular mechanisms of action of camptothecin-type drugs","volume":"26","author":"Legarza","year":"2006","journal-title":"Anticancer Res"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1385\/1-59259-866-8:343","author":"Stewart","year":"2005","journal-title":"Camptothecins in cancer therapy"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.bcp.2010.04.016","article-title":"Small molecule modulation of HH-GLI signaling: current leads, trials and tribulations","volume":"80","author":"Mas","year":"2010","journal-title":"Biochem Pharmacol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.semcancer.2021.04.003","article-title":"Hedgehog signaling mechanism and role in cancer","volume":"85","author":"Jiang","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"ref50","first-page":"670","article-title":"Vismodegib (Erivedge) for advanced basal cell carcinoma","volume":"37","author":"Fellner","year":"2012","journal-title":"Drug Forecast"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/978-3-319-91442-8_9","article-title":"Vismodegib","volume":"211","author":"Meiss","year":"2018","journal-title":"Recent Results Cancer Res"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1186\/s40478-019-0773-8","article-title":"Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis","volume":"7","author":"Li","year":"2019","journal-title":"Acta Neuropathol Commun"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1200\/JCO.2014.60.1591","article-title":"Vismodegib exerts targeted efficacy against recurrent sonic hedgehog-subgroup medulloblastoma: results from phase II pediatric brain tumor consortium studies PBTC-025B and PBTC-032","volume":"33","author":"Robinson","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1038\/nrm3979","article-title":"Regulation of RAF protein kinases in ERK signalling","volume":"16","author":"Lavoie","year":"2015","journal-title":"Nat Rev Mol Cell Biol"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.ccell.2017.08.017","article-title":"Integrated molecular meta-analysis of 1,000 pediatric high-grade and diffuse intrinsic pontine glioma","volume":"32","author":"Mackay","year":"2017","journal-title":"Cancer Cell"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.3390\/cancers14174264","volume":"14","author":"Talloa","year":"2022","journal-title":"Cancers"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1470-2045(19)30277-3","article-title":"Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial","volume":"20","author":"Fangusaro","year":"2019","journal-title":"Lancet Oncol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1200\/JCO.21.02840","article-title":"Phase II study of selumetinib in children and young adults with tumors harboring activating mitogen-activated protein kinase pathway genetic alterations: arm E of the NCI-COG pediatric MATCH trial","volume":"40","author":"Eckstein","year":"2022","journal-title":"J Clin Oncol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.18632\/oncotarget.27600","volume":"11","author":"Nicolaides","year":"2020","journal-title":"Oncotarget"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"7303","DOI":"10.1158\/1078-0432.CCR-19-2177","volume":"25","author":"Hargrave","year":"2019","journal-title":"Clin Cancer Res"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"10505","DOI":"10.1200\/JCO.2018.36.15_suppl.10505","volume":"36","author":"Hargrave","year":"2018","journal-title":"J Clin Oncol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"e048975","DOI":"10.1136\/bmjopen-2021-048975","article-title":"Efficacy and safety of bevacizumab in the treatment of adult gliomas: a systematic review and meta-analysis","volume":"11","author":"Wang","year":"2021","journal-title":"BMJ Open"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1007\/s12094-015-1389-5","article-title":"Safety of bevacizumab in patients younger than 4 years of age","volume":"18","author":"Millan","year":"2016","journal-title":"Clin Transl Oncol"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/bcp.12778","article-title":"Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation","volume":"81","author":"Han","year":"2016","journal-title":"Brit J Clinical Pharma"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"100115","DOI":"10.1016\/j.ejcped.2023.100115","article-title":"Use of bevacizumab in pediatric low-grade glioma: ten-year experience in a single center","volume":"2","author":"Sim\u00e3o-Rafael","year":"2023","journal-title":"EJC Paediatr Oncol"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s11060-015-1754-9","article-title":"Decreased tumor apparent diffusion coefficient correlates with objective response of pediatric low-grade glioma to bevacizumab","volume":"122","author":"Hsu","year":"2015","journal-title":"J Neurooncol"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1023\/A:1016222202230","article-title":"Immunohistochemical markers for prognosis of ependymal neoplasms","volume":"58","author":"Korshunov","year":"2002","journal-title":"J Neuro Oncol"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1093\/neuonc\/noq033","article-title":"Bevacizumab in recurrent high-grade pediatric gliomas","volume":"12","author":"Narayana","year":"2010","journal-title":"Neuro-Oncology"},{"key":"ref69","first-page":"1","article-title":"Checkpoint immunotherapy in pediatrics: here, gone, and back again","volume":"42","author":"Long","year":"2022","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"7168","DOI":"10.1158\/0008-5472.CAN-14-2458","article-title":"Trafficking of T cells into tumors","volume":"74","author":"Slaney","year":"2014","journal-title":"Cancer Res"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N Engl J Med"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"e1433518","DOI":"10.1080\/2162402X.2018.1433518","article-title":"Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma","volume":"7","author":"Quintarelli","year":"2018","journal-title":"Oncoimmunology"},{"key":"ref75","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/s41423-024-01226-x","article-title":"Immunotherapy for glioblastoma: current state, challenges, and future perspectives","volume":"21","author":"Liu","year":"2024","journal-title":"Cell Mol Immunol"},{"key":"ref76","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1080\/1941126X.2018.1444339","article-title":"Rayyan for systematic reviews","volume":"30","author":"Johnson","year":"2018","journal-title":"J Electron Resour Librariansh"},{"key":"ref77","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1002\/mpo.2950230507","article-title":"High-dose chemotherapy with marrow reinfusion and hyperfractionated irradiation for children with high-risk brain tumors","volume":"23","author":"Kedar","year":"1994","journal-title":"Med Pediatr Oncol"},{"key":"ref78","doi-asserted-by":"crossref","first-page":"3666","DOI":"10.1002\/1097-0142(19930601)71:11<3666::AID-CNCR2820711132>3.0.CO;2-E","article-title":"A phase I study of ifosfamide given on alternate days to treat children with brain tumors","volume":"71","author":"Pratt","year":"1993","journal-title":"Cancer"},{"key":"ref79","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1097\/00043426-199505000-00006","article-title":"A phase I and II trial of dose-intensified cyclophosphamide and GM-CSF in pediatric malignant brain tumors","volume":"17","author":"Abrahamsen","year":"1995","journal-title":"J Pediatr Hematol Oncol"},{"key":"ref80","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/(SICI)1096-911X(199801)30:1<28::AID-MPO9>3.0.CO;2-2","article-title":"Carboplatin and etoposide with hyperfractionated radiotherapy in children with newly diagnosed diffuse pontine gliomas: a phase I\/II study","volume":"30","author":"Walter","year":"1998","journal-title":"Med Pediatr Oncol"},{"key":"ref81","doi-asserted-by":"crossref","first-page":"4453","DOI":"10.1200\/JCO.22.02768","article-title":"Carboplatin dosage: prospective evaluation of a simple formula based on renal function","volume":"41","author":"Calvert","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref82","volume":"23","year":"1993","journal-title":"A manual for participants in clinical trials of investigational agent"},{"key":"ref83","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1002\/1097-0142(19910801)68:3<474::AID-CNCR2820680305>3.0.CO;2-7","article-title":"Clinical trials hyperfractionated radiation therapy in brain stem tumors results of treatment at the 7020 cGy dose level of pediatric oncology group study #8495","volume":"68","author":"Freeman","year":"1991","journal-title":"Cancer"},{"key":"ref84","first-page":"S3","article-title":"Taxol (paclitaxel): mechanisms of action","volume":"5 Suppl 6","author":"Horwitz","year":"1994","journal-title":"Ann Oncol"},{"key":"ref85","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/BF00686276","volume":"33","author":"Cahan","year":"1994","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref86","first-page":"3495","article-title":"Taxol sensitizes human astrocytoma cells to radiation","volume":"52","author":"Tishler","year":"1992","journal-title":"Cancer Res"},{"key":"ref87","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1200\/JCO.1995.13.8.2066","article-title":"Salvage chemotherapy with paclitaxel for recurrent primary brain tumors","volume":"13","author":"Chamberlain","year":"1995","journal-title":"J Clin Oncol"},{"key":"ref88","first-page":"733","article-title":"Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative pediatric oncology branch, national cancer institute and children\u2019s cancer group trial","volume":"5","author":"Seibel","year":"1999","journal-title":"Clin Cancer Res"},{"key":"ref89","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1002\/mpo.1215","article-title":"A phase I study of cranial radiation therapy with concomitant continuous infusion paclitaxel in children with brain tumors","volume":"37","author":"Liu","year":"2001","journal-title":"Med Pediatr Oncol"},{"key":"ref90","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s002800100356","article-title":"Phase I trial of lobradimil (RMP-7) and carboplatin in children with brain tumors","volume":"48","author":"Warren","year":"2001","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref91","doi-asserted-by":"crossref","first-page":"105","DOI":"10.2165\/00003088-200140020-00003","article-title":"The development of the bradykinin agonist labradimil as a means to increase the permeability of the blood-brain barrier: from concept to clinical evaluation","volume":"40","author":"Emerich","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"ref92","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1002\/cncr.10814","article-title":"Phase I study of fotemustine in pediatric patients with refractory brain tumors","volume":"95","author":"Hargrave","year":"2002","journal-title":"Cancer"},{"key":"ref93","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1002\/cncr.20168","article-title":"Oral topotecan in children with recurrent or progressive high-grade glioma: a Phase I\/II study by the German society for pediatric oncology and hematology","volume":"100","author":"Wagner","year":"2004","journal-title":"Cancer"},{"key":"ref94","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/pbc.20382","article-title":"Etoposide, vincristine, and cyclosporin A with standard-dose radiation therapy in newly diagnosed diffuse intrinsic brainstem gliomas: a pediatric oncology group phase I study","volume":"45","author":"Greenberg","year":"2005","journal-title":"Pediatr Blood Cancer"},{"key":"ref95","doi-asserted-by":"crossref","first-page":"S40","DOI":"10.1006\/clin.1996.0140","article-title":"The mechanism of action of cyclosporin A and FK506","volume":"80","author":"Ho","year":"1996","journal-title":"Clin Immunol Immunopathol"},{"key":"ref96","first-page":"1","author":"Agrawal","year":"2007","journal-title":"xPharm: the comprehensive pharmacology reference"},{"key":"ref97","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1200\/JCO.2005.06.544","article-title":"Phase I clinical trial of mafosfamide in infants and children aged 3 years or younger with newly diagnosed embryonal tumors: a pediatric brain tumor consortium study (PBTC-001)","volume":"23","author":"Blaney","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref98","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/BF00232343","volume":"2","author":"Alberts","year":"1984","journal-title":"Investig New Drugs"},{"key":"ref99","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1200\/JCO.1987.5.3.459","article-title":"Carboplatin and recurrent childhood brain tumors","volume":"5","author":"Allen","year":"1987","journal-title":"J Clin Oncol"},{"key":"ref100","first-page":"1103","article-title":"Phase I clinical and pharmacologic trial of carboplatin daily for 5 days","volume":"68","author":"Van Echo","year":"1984","journal-title":"Cancer Treat Rep"},{"key":"ref101","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1002\/1097-0142(19860115)57:2<222::AID-CNCR2820570206>3.0.CO;2-X","article-title":"Phase I clinical trial and pharmacokinetics of carboplatin (NSC 241240) by single monthly 30-minute infusion","volume":"57","author":"Koeller","year":"1986","journal-title":"Cancer"},{"key":"ref102","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1200\/JCO.1989.7.5.651","article-title":"A phase I clinical and pharmacokinetic study of carboplatin and autologous bone marrow support","volume":"7","author":"Shea","year":"1989","journal-title":"J Clin Oncol"},{"key":"ref103","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s11060-004-1366-2","article-title":"A study of sequential high dose cyclophosphamide and high dose carboplatin with peripheral stem-cell rescue in resistant or recurrent pediatric brain tumors","volume":"71","author":"Foreman","year":"2005","journal-title":"J Neurooncol"},{"key":"ref104","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1016\/j.ejca.2006.03.023","article-title":"Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours","volume":"42","author":"Baruchel","year":"2006","journal-title":"Eur J Cancer"},{"key":"ref105","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1158\/1078-0432.CCR-05-2094","article-title":"Phase I trial of intrathecal spartaject busulfan in children with neoplastic meningitis: a pediatric brain tumor consortium study (PBTC-004)","volume":"12","author":"Gururangan","year":"2006","journal-title":"Clin Cancer Res"},{"key":"ref106","doi-asserted-by":"crossref","first-page":"6712","DOI":"10.1158\/1078-0432.CCR-07-1016","volume":"13","author":"Broniscer","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref107","doi-asserted-by":"crossref","first-page":"3137","DOI":"10.1200\/JCO.2006.09.4243","article-title":"Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a pediatric brain tumor consortium study","volume":"25","author":"Kieran","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref108","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s40265-020-01464-z","article-title":"Lonafarnib: first approval","volume":"81","author":"Dhillon","year":"2021","journal-title":"Drugs"},{"key":"ref109","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1215\/15228517-2006-031","article-title":"Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a pediatric brain tumor consortium report","volume":"9","author":"Pollack","year":"2007","journal-title":"Neuro Oncol"},{"key":"ref110","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1073\/pnas.0408283102","article-title":"A non-ATP-competitive inhibitor of BCR-ABL overrides imatinib resistance","volume":"102","author":"Gumireddy","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref111","first-page":"5143","article-title":"Intracranial inhibition of platelet-derived growth factor-mediated glioblastoma cell growth by an orally active kinase inhibitor of the 2-phenylaminopyrimidine class","volume":"60","author":"Kilic","year":"2000","journal-title":"Cancer Res"},{"key":"ref112","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1200\/JCO.2007.14.1812","article-title":"Phase I clinical trial of cilengitide in children with refractory brain tumors: pediatric brain tumor consortium study PBTC-012","volume":"26","author":"MacDonald","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref113","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/S0959-8049(03)00057-1","article-title":"Phase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins \u03b1v\u03b23 and \u03b1v\u03b25 in patients with advanced solid tumours","volume":"39","author":"Eskens","year":"2003","journal-title":"Eur J Cancer"},{"key":"ref114","first-page":"240","article-title":"Activity of VNP40101M (Cloretazine) in the treatment of CNS tumor xenografts in athymic mice","volume":"9","author":"Badruddoja","year":"2007","journal-title":"Neurooncol"},{"key":"ref115","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1200\/JCO.2006.07.0961","article-title":"Cloretazine (VNP40101M), a novel sulfonylhydrazine alkylating agent, in patients age 60 years or older with previously untreated acute myeloid leukemia","volume":"25","author":"Giles","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref116","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1158\/1078-0432.CCR-03-0738","article-title":"A phase I and pharmacokinetic study of VNP40101M, a novel sulfonylhydrazine alkylating agent, in patients with refractory leukemia","volume":"10","author":"Giles","year":"2004","journal-title":"Clin Cancer Res"},{"key":"ref117","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1158\/1078-0432.CCR-07-4242","article-title":"Phase I trial of VNP40101M (cloretazine) in children with recurrent brain tumors: a pediatric brain tumor consortium study","volume":"14","author":"Gururangan","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref118","first-page":"3033","article-title":"Sartorelli AC. 1,2-Bis(methylsulfonyl)-1-(2-chloroethyl)-2-(methylamino)carbonylhydrazine (101M): a novel sulfonylhydrazine prodrug with broad-spectrum antineoplastic activity","volume":"61","author":"Finch","year":"2001","journal-title":"Cancer Res"},{"key":"ref119","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1215\/15228517-2008-004","article-title":"Phase I trial of tipifarnib in children with newly diagnosed intrinsic diffuse brainstem glioma","volume":"10","author":"Haas-Kogan","year":"2008","journal-title":"Neuro Oncol"},{"key":"ref120","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/S0955-0674(99)00072-1","article-title":"Farnesyltransferase inhibitors: antineoplastic mechanism and clinical prospects","volume":"12","author":"Prendergast","year":"2000","journal-title":"Curr Opin Cell Biol"},{"key":"ref121","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/pbc.21873","article-title":"Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors","volume":"52","author":"Kieran","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"ref122","first-page":"99","article-title":"SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1\/KDR) that inhibits tyrosine kinase catalysis, tumor vascularization, and growth of multiple tumor types","volume":"59","author":"Fong","year":"1999","journal-title":"Cancer Res"},{"key":"ref123","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1016\/j.ejca.2010.05.016","article-title":"Phase I study of temozolomide combined with oral etoposide in children with recurrent or progressive medulloblastoma","volume":"46","author":"Ruggiero","year":"2010","journal-title":"Eur J Cancer"},{"key":"ref124","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1200\/JCO.2004.06.032","article-title":"Clinical, histopathologic, and molecular markers of prognosis: toward a new disease risk stratification system for medulloblastoma","volume":"22","author":"Gajjar","year":"2004","journal-title":"J Clin Oncol"},{"key":"ref125","first-page":"3054","article-title":"ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease","volume":"8","author":"Gilbertson","year":"2002","journal-title":"Clin Cancer Res"},{"key":"ref126","first-page":"3620","article-title":"ERBB1 is amplified and overexpressed in high-grade diffusely infiltrative pediatric brain stem glioma","volume":"9","author":"Gilbertson","year":"2003","journal-title":"Clin Cancer Res"},{"key":"ref127","first-page":"1165","volume":"9","author":"Hudziak","year":"1989","journal-title":"Mol Cell Biol"},{"key":"ref128","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/S1535-6108(04)00083-2","article-title":"Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex","volume":"5","author":"Franklin","year":"2004","journal-title":"Cancer Cell"},{"key":"ref129","first-page":"4838","article-title":"Induction of apoptosis and cell cycle arrest by CP-358,774, an inhibitor of epidermal growth factor receptor tyrosine kinase","volume":"57","author":"Moyer","year":"1997","journal-title":"Cancer Res"},{"key":"ref130","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/S1470-2045(03)01137-9","article-title":"Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer","volume":"4","author":"Sridhar","year":"2003","journal-title":"Lancet Oncol"},{"key":"ref131","doi-asserted-by":"crossref","first-page":"6255","DOI":"10.1038\/sj.onc.1205794","article-title":"Anti-tumor activity of GW572016: a dual tyrosine kinase inhibitor blocks EGF activation of EGFR\/erbB2 and downstream Erk1\/2 and AKT pathways","volume":"21","author":"Xia","year":"2002","journal-title":"Oncogene"},{"key":"ref132","doi-asserted-by":"crossref","first-page":"4221","DOI":"10.1200\/JCO.2010.28.4687","article-title":"Phase I trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study","volume":"28","author":"Fouladi","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref133","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1093\/neuonc\/noq141","article-title":"Innovative therapies for children with cancer pediatric phase I study of erlotinib in brainstem glioma and relapsing\/refractory brain tumors","volume":"13","author":"Geoerger","year":"2011","journal-title":"Neuro Oncol"},{"key":"ref134","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.hoc.2007.08.013","article-title":"Preclinical studies of novel targeted therapies","volume":"21","author":"Hideshima","year":"2007","journal-title":"Hematol Oncol Clin North Am"},{"key":"ref135","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1200\/JCO.2010.31.3601","article-title":"Phase I trial of lenalidomide in pediatric patients with recurrent, refractory, or progressive primary CNS tumors: pediatric Brain Tumor Consortium study PBTC-018","volume":"29","author":"Warren","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref136","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/neuonc\/nos315","article-title":"Phase I trial of capecitabine rapidly disintegrating tablets and concomitant radiation therapy in children with newly diagnosed brainstem gliomas and high-grade gliomas","volume":"15","author":"Kilburn","year":"2013","journal-title":"Neuro Oncol"},{"key":"ref137","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2165\/00003088-200140020-00002","article-title":"Clinical pharmacokinetics of capecitabine","volume":"40","author":"Reigner","year":"2001","journal-title":"Clin Pharmacokinet"},{"key":"ref138","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1002\/pbc.24541","article-title":"A pediatric phase 1 trial of vorinostat and temozolomide in relapsed or refractory primary brain or spinal cord tumors: a children\u2019s oncology group phase 1 consortium study","volume":"60","author":"Hummel","year":"2013","journal-title":"Pediatr Blood Cancer"},{"key":"ref139","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1517\/13543784.16.7.1111","article-title":"Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma","volume":"16","author":"Duvic","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"ref140","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1200\/JCO.2009.25.9119","article-title":"Pediatric phase I trial and pharmacokinetic study of vorinostat: a children\u2019s oncology group phase I consortium report","volume":"28","author":"Fouladi","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref141","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","article-title":"Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer","volume":"23","author":"Kelly","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref142","doi-asserted-by":"crossref","first-page":"6305","DOI":"10.1158\/1078-0432.CCR-13-1425","article-title":"Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study","volume":"19","author":"Gajjar","year":"2013","journal-title":"Clin Cancer Res"},{"key":"ref143","doi-asserted-by":"crossref","first-page":"3050","DOI":"10.1158\/1078-0432.CCR-13-0306","article-title":"Phase I trial, pharmacokinetics, and pharmacodynamics of vandetanib and dasatinib in children with newly diagnosed diffuse intrinsic pontine glioma","volume":"19","author":"Broniscer","year":"2013","journal-title":"Clin Cancer Res"},{"key":"ref144","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1038\/sj.bjc.6604988","article-title":"Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma","volume":"100","author":"Yoshikawa","year":"2009","journal-title":"Br J Cancer"},{"key":"ref145","doi-asserted-by":"crossref","first-page":"1527","DOI":"10.1124\/mol.105.020172","article-title":"Potent inhibition of platelet-derived growth factor-induced responses in vascular smooth muscle cells by BMS-354825 (dasatinib)","volume":"69","author":"Chen","year":"2006","journal-title":"Mol Pharmacol"},{"key":"ref146","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1093\/neuonc\/not021","article-title":"A phase I trial of arsenic trioxide chemoradiotherapy for infiltrating astrocytomas of childhood","volume":"15","author":"Cohen","year":"2013","journal-title":"Neuro Oncol"},{"key":"ref147","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2174\/138920106779116829","article-title":"Arsenic trioxide in hematological malignancies: the new discovery of an ancient drug","volume":"7","author":"Bonati","year":"2006","journal-title":"Curr Pharm Biotechnol"},{"key":"ref148","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1182\/blood-2007-08-107839","article-title":"Phase 1 trial and pharmacokinetic study of arsenic trioxide in children and adolescents with refractory or relapsed acute leukemia, including acute promyelocytic leukemia or lymphoma","volume":"111","author":"Fox","year":"2008","journal-title":"Blood"},{"key":"ref149","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1093\/neuonc\/nou103","article-title":"A phase I trial of veliparib (ABT-888) and temozolomide in children with recurrent CNS tumors: a pediatric brain tumor consortium report","volume":"16","author":"Su","year":"2014","journal-title":"Neuro Oncol"},{"key":"ref150","doi-asserted-by":"crossref","first-page":"2728","DOI":"10.1158\/1078-0432.CCR-06-3039","article-title":"ABT-888, an orally active poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models","volume":"13","author":"Donawho","year":"2007","journal-title":"Clin Cancer Res"},{"key":"ref151","first-page":"1939","article-title":"Pediatric patients with refractory central nervous system tumors: experiences of a clinical trial combining bevacizumab and temsirolimus","volume":"34","author":"Piha-Paul","year":"2014","journal-title":"Anticancer Res"},{"key":"ref152","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1158\/1078-0432.CCR-07-4719","article-title":"Temsirolimus, an inhibitor of mammalian target of rapamycin","volume":"14","author":"Rini","year":"2008","journal-title":"Clin Cancer Res"},{"key":"ref153","unstructured":"Piha-Paul SA. An innovative phase I trial design allowing for the identification an innovative phase I trial design allowing for the identification of multiple potential maximum tolerated doses with of multiple potential maximum tolerated doses with combination therapy of targeted agents combination therapy of targeted agents [master's thesis]. Austin, TX, USA: University of Texas; 2010."},{"key":"ref154","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1093\/neuonc\/nou114","article-title":"A phase 1 and pharmacokinetic study of enzastaurin in pediatric patients with refractory primary central nervous system tumors: a pediatric brain tumor consortium study","volume":"17","author":"Kilburn","year":"2015","journal-title":"Neuro-Oncology"},{"key":"ref155","doi-asserted-by":"crossref","first-page":"4092","DOI":"10.1200\/JCO.2005.05.3447","article-title":"Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer","volume":"24","author":"Carducci","year":"2006","journal-title":"J Clin Oncol"},{"key":"ref156","doi-asserted-by":"crossref","first-page":"7462","DOI":"10.1158\/0008-5472.CAN-05-0071","article-title":"The protein kinase Cbeta-selective inhibitor, Enzastaurin (LY317615.HCl), suppresses signaling through the AKT pathway, induces apoptosis, and suppresses growth of human colon cancer and glioblastoma xenografts","volume":"65","author":"Graff","year":"2005","journal-title":"Cancer Res"},{"key":"ref157","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s11060-014-1665-1","article-title":"Phase I and pharmacokinetic trial of PTC299 in pediatric patients with refractory or recurrent central nervous system tumors: a PBTC study","volume":"121","author":"Packer","year":"2015","journal-title":"J Neurooncol"},{"key":"ref158","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/sj.onc.1202019","article-title":"Regulation of vascular endothelial growth factor (VEGF) expression is mediated by internal initiation of translation and alternative initiation of transcription","volume":"17","author":"Akiri","year":"1998","journal-title":"Oncogene"},{"key":"ref159","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s00280-015-2781-0","article-title":"Phase I study of non-pegylated liposomal doxorubicin in children with recurrent\/refractory high-grade glioma","volume":"76","author":"Chastagner","year":"2015","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref160","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of pegylated liposomal doxorubicin","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin Pharmacokinet"},{"key":"ref161","doi-asserted-by":"crossref","first-page":"e61512","DOI":"10.1371\/journal.pone.0061512","volume":"8","author":"Veringa","year":"2013","journal-title":"PLoS One"},{"key":"ref162","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/cncr.10201","article-title":"Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma","volume":"94","author":"Harris","year":"2002","journal-title":"Cancer"},{"key":"ref163","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1054\/bjoc.2000.1459","article-title":"High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours","volume":"83","author":"Koukourakis","year":"2000","journal-title":"Br J Cancer"},{"key":"ref164","doi-asserted-by":"crossref","first-page":"1433","DOI":"10.1007\/s00381-015-2812-5","article-title":"A phase I trial and PK study of cediranib (AZD2171), an orally bioavailable pan-VEGFR inhibitor, in children with recurrent or refractory primary CNS tumors","volume":"31","author":"Kieran","year":"2015","journal-title":"Child\u2019s Nerv Syst"},{"key":"ref165","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ccr.2006.11.021","article-title":"AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients","volume":"11","author":"Batchelor","year":"2007","journal-title":"Cancer Cell"},{"key":"ref166","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1007\/s00381-015-2725-3","article-title":"Phase I trial of weekly MK-0752 in children with refractory central nervous system malignancies: a pediatric brain tumor consortium study","volume":"31","author":"Hoffman","year":"2015","journal-title":"Childs Nerv Syst"},{"key":"ref167","first-page":"943","article-title":"Gamma secretase inhibitors of Notch signaling","volume":"6","author":"Olsauskas-Kuprys","year":"2013","journal-title":"Onco Targets Ther"},{"key":"ref168","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1002\/pbc.25687","article-title":"A phase 1 trial of TPI 287 as a single agent and in combination with temozolomide in patients with refractory or recurrent neuroblastoma or medulloblastoma","volume":"63","author":"Mitchell","year":"2016","journal-title":"Pediatr Blood Cancer"},{"key":"ref169","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1158\/1535-7163.MCT-12-0061","article-title":"TPI-287, a new taxane family member, reduces the brain metastatic colonization of breast cancer cells","volume":"11","author":"Fitzgerald","year":"2012","journal-title":"Mol Cancer Ther"},{"key":"ref170","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1093\/neuonc\/now282","article-title":"A phase I trial of the MEK inhibitor selumetinib (AZD6244) in pediatric patients with recurrent or refractory low-grade glioma: a Pediatric Brain Tumor Consortium (PBTC) study","volume":"19","author":"Banerjee","year":"2017","journal-title":"Neuro Oncol"},{"key":"ref171","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1517\/13543784.2015.982275","article-title":"Selumetinib for the treatment of cancer","volume":"24","author":"Ciombor","year":"2015","journal-title":"Expert Opin Investig Drugs"},{"key":"ref172","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11060-017-2575-9","article-title":"A phase I\/II study of gemcitabine during radiotherapy in children with newly diagnosed diffuse intrinsic pontine glioma","volume":"135","author":"Veldhuijzen van Zanten","year":"2017","journal-title":"J Neurooncol"},{"key":"ref173","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1093\/ajhp\/54.2.162","article-title":"Gemcitabine: a cytidine analogue active against solid tumors","volume":"54","author":"Hui","year":"1997","journal-title":"Am J Health Syst Pharm"},{"key":"ref174","doi-asserted-by":"crossref","first-page":"e0178593","DOI":"10.1371\/journal.pone.0178593","article-title":"A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors","volume":"12","author":"Becher","year":"2017","journal-title":"PLoS One"},{"key":"ref175","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1517\/17425255.2012.681376","article-title":"Perifosine, an oral, anti-cancer agent and inhibitor of the Akt pathway: mechanistic actions, pharmacodynamics, pharmacokinetics, and clinical activity","volume":"8","author":"Richardson","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"ref176","doi-asserted-by":"crossref","first-page":"e27035","DOI":"10.1002\/pbc.27035","article-title":"Phase 1 trial, pharmacokinetics, and pharmacodynamics of dasatinib combined with crizotinib in children with recurrent or progressive high-grade and diffuse intrinsic pontine glioma","volume":"65","author":"Broniscer","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"ref177","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1158\/1535-7163.MCT-13-0499","article-title":"Crizotinib, a c-Met inhibitor, prevents metastasis in a metastatic uveal melanoma model","volume":"12","author":"Surriga","year":"2013","journal-title":"Mol Cancer Ther"},{"key":"ref178","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1007\/s11060-020-03627-0","article-title":"A phase I trial of lenalidomide and radiotherapy in children with diffuse intrinsic pontine gliomas or high-grade gliomas","volume":"149","author":"Hipp","year":"2020","journal-title":"J Neurooncol"},{"key":"ref179","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1007\/s11060-020-03641-2","article-title":"A phase I\/II study of ribociclib following radiation therapy in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG)","volume":"149","author":"DeWire","year":"2020","journal-title":"J Neurooncol"},{"key":"ref180","doi-asserted-by":"crossref","first-page":"4001","DOI":"10.1080\/21691401.2019.1670670","article-title":"Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4\/6-cyclin D-Rb-E2F pathway","volume":"47","author":"Li","year":"2019","journal-title":"Artif Cells Nanomed Biotechnol"},{"key":"ref181","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1158\/1078-0432.CCR-16-2898","article-title":"A phase I study of the CDK4\/6 inhibitor ribociclib (LEE011) in pediatric patients with malignant rhabdoid tumors, neuroblastoma, and other solid tumors","volume":"23","author":"Geoerger","year":"2017","journal-title":"Clin Cancer Res"},{"key":"ref182","doi-asserted-by":"crossref","first-page":"2442","DOI":"10.1158\/1078-0432.CCR-20-4078","article-title":"A phase I and surgical study of ribociclib and everolimus in children with recurrent or refractory malignant brain tumors: a pediatric brain tumor consortium study","volume":"27","author":"DeWire","year":"2021","journal-title":"Clin Cancer Res"},{"key":"ref183","doi-asserted-by":"crossref","first-page":"4806","DOI":"10.1200\/JCO.2007.11.4017","article-title":"Phase I study of everolimus in pediatric patients with refractory solid tumors","volume":"25","author":"Fouladi","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref184","article-title":"Phase I study of ribociclib and everolimus in children with newly diagnosed DIPG and high-grade glioma: a CONNECT pediatric neuro-oncology consortium report","volume":"4","author":"DeWire","year":"2022","journal-title":"Neurooncol Adv"},{"key":"ref185","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1038\/nature00766","article-title":"Mutations of the BRAF gene in human cancer","volume":"417","author":"Davies","year":"2002","journal-title":"Nature"},{"key":"ref186","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1002\/jcph.1617","article-title":"Population pharmacokinetics of vemurafenib in children with recurrent\/refractory BRAF gene V600E-mutant astrocytomas","volume":"60","author":"Wang","year":"2020","journal-title":"J Clin Pharmacol"},{"key":"ref187","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1093\/neuonc\/noaa016","article-title":"A phase I\/II study of veliparib (ABT-888) with radiation and temozolomide in newly diagnosed diffuse pontine glioma: a pediatric brain tumor consortium study","volume":"22","author":"Baxter","year":"2020","journal-title":"Neuro Oncol"},{"key":"ref188","doi-asserted-by":"crossref","first-page":"e28879","DOI":"10.1002\/pbc.28879","article-title":"A phase I trial of the CDK 4\/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: a pediatric brain tumor consortium study (PBTC-042)","volume":"68","author":"Van Mater","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"ref189","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1177\/87551225231205153","article-title":"Updated review article: cyclin-dependent kinase 4\/6 inhibitor impact, FDA approval, and resistance pathways","volume":"39","author":"Hunter","year":"2023","journal-title":"J Pharm Technol"},{"key":"ref190","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1470-2045(14)71159-3","article-title":"The cyclin-dependent kinase 4\/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1\/TRIO-18): a randomised phase 2 study","volume":"16","author":"Finn","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref191","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s11060-021-03763-1","article-title":"A phase I\/II study of bevacizumab, irinotecan and erlotinib in children with progressive diffuse intrinsic pontine glioma","volume":"153","author":"El-Khouly","year":"2021","journal-title":"J Neurooncol"},{"key":"ref192","doi-asserted-by":"crossref","first-page":"e28756","DOI":"10.1002\/pbc.28756","article-title":"Phase 1 study of pomalidomide in children with recurrent, refractory, and progressive central nervous system tumors: a pediatric brain tumor consortium trial","volume":"68","author":"Fangusaro","year":"2021","journal-title":"Pediatr Blood Cancer"},{"key":"ref193","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-3-319-91439-8_8","volume":"212","author":"Engelhardt","year":"2018","journal-title":"Recent results in cancer research"},{"key":"ref194","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1200\/JCO.2007.12.2440","article-title":"Bevacizumab plus irinotecan in recurrent glioblastoma multiforme","volume":"25","author":"Vredenburgh","year":"2007","journal-title":"J Clin Oncol"},{"key":"ref195","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref196","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s00381-022-05479-7","article-title":"A phase I study of irinotecan and temozolomide with bevacizumab in children with recurrent\/refractory central nervous system tumors","volume":"38","author":"Metts","year":"2022","journal-title":"Childs Nerv Syst"},{"key":"ref197","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00280-021-04357-4","article-title":"Population pharmacokinetic analysis of crizotinib in children with progressive\/recurrent high-grade and diffuse intrinsic pontine gliomas","volume":"88","author":"Gibson","year":"2021","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref198","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1007\/s00280-022-04412-8","article-title":"Population pharmacokinetics of crenolanib in children and young adults with brain tumors","volume":"89","author":"Bisbee","year":"2022","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref199","doi-asserted-by":"crossref","first-page":"5319","DOI":"10.1073\/pnas.1320661111","article-title":"Crenolanib is a selective type I pan-FLT3 inhibitor","volume":"111","author":"Smith","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref200","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.1200\/JCO.2009.21.8487","article-title":"Phase I study of the safety, tolerability, and pharmacokinetics of oral CP-868, 596, a highly specific platelet-derived growth factor receptor tyrosine kinase inhibitor in patients with advanced cancers","volume":"27","author":"Lewis","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref201","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/neuonc\/noab188","article-title":"Phase I\/II trial of vorinostat and radiation and maintenance vorinostat in children with diffuse intrinsic pontine glioma: a children\u2019s oncology group report","volume":"24","author":"Su","year":"2022","journal-title":"Neuro Oncol"},{"key":"ref202","doi-asserted-by":"crossref","first-page":"2262","DOI":"10.1093\/neuonc\/noad141","article-title":"Phase I trial of panobinostat in children with diffuse intrinsic pontine glioma: a report from the Pediatric Brain Tumor Consortium (PBTC-047)","volume":"25","author":"Monje","year":"2023","journal-title":"Neuro Oncol"},{"key":"ref203","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/nm.3855","article-title":"Functionally defined therapeutic targets in diffuse intrinsic pontine glioma","volume":"21","author":"Grasso","year":"2015","journal-title":"Nat Med"},{"key":"ref204","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1007\/s10637-011-9666-9","article-title":"A phase I study of oral panobinostat (LBH589) in Japanese patients with advanced solid tumors","volume":"30","author":"Fukutomi","year":"2012","journal-title":"Invest New Drugs"},{"key":"ref205","doi-asserted-by":"crossref","first-page":"2074","DOI":"10.1093\/neuonc\/noad105","article-title":"PNOC015: repeated convection-enhanced delivery of MTX110 (aqueous panobinostat) in children with newly diagnosed diffuse intrinsic pontine glioma","volume":"25","author":"Mueller","year":"2023","journal-title":"Neuro Oncol"},{"key":"ref206","doi-asserted-by":"crossref","first-page":"127","DOI":"10.3171\/2020.2.PEDS19786","article-title":"High-dose MTX110 (soluble panobinostat) safely administered into the fourth ventricle in a nonhuman primate model","volume":"26","author":"Sandberg","year":"2020","journal-title":"J Neurosurg Pediatr"},{"key":"ref207","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1111\/bpa.12082","article-title":"Convection-enhanced drug delivery to the brain: therapeutic potential and neuropathological considerations","volume":"24","author":"Barua","year":"2014","journal-title":"Brain Pathol"},{"key":"ref208","first-page":"190","article-title":"Real-time image-guided direct convective perfusion of intrinsic brainstem lesions","volume":"107","author":"Lonser","year":"2007","journal-title":"Technical Note J Neurosurg"},{"key":"ref209","first-page":"S155","article-title":"Safety and pharmacokinetics of ONC201 (dordaviprone) administered two consecutive days per week in pediatric patients with H3 K27M-mutant glioma","volume":"26","author":"Odia","year":"2024","journal-title":"Neurooncol"},{"key":"ref210","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1124\/molpharm.121.000336","volume":"100","author":"Free","year":"2021","journal-title":"Mol Pharmacol"},{"key":"ref211","doi-asserted-by":"crossref","first-page":"e30874","DOI":"10.1002\/pbc.30874","article-title":"A phase 1 study of mebendazole with bevacizumab and irinotecan in high-grade gliomas","volume":"71","author":"Krystal","year":"2024","journal-title":"Pediatr Blood Cancer"},{"key":"ref212","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1093\/neuonc\/noad174","article-title":"Indoximod-based chemo-immunotherapy for pediatric brain tumors: a first-in-children phase I trial","volume":"26","author":"Johnson","year":"2024","journal-title":"Neuro Oncol"},{"key":"ref213","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1016\/j.immuni.2021.09.005","article-title":"Inhibition of the BTK-IDO-mTOR axis promotes differentiation of monocyte-lineage dendritic cells and enhances anti-tumor T cell immunity","volume":"54","author":"Sharma","year":"2021","journal-title":"Immunity"},{"key":"ref214","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1073\/pnas.1117736109","article-title":"Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase","volume":"109","author":"Ravishankar","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref215","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2051-1426-2-21","article-title":"The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma","volume":"2","author":"Li","year":"2014","journal-title":"J Immunother Cancer"},{"key":"ref216","doi-asserted-by":"crossref","first-page":"2769","DOI":"10.1200\/JCO.23.02019","article-title":"Phase I trial of GD2.CART cells augmented with constitutive interleukin-7 receptor for treatment of high-grade pediatric CNS tumors","volume":"42","author":"Lin","year":"2024","journal-title":"J Clin Oncol"},{"key":"ref217","unstructured":"Study Details. A phase I\/II study of Ribociclib,a CDK4\/6 inhibitor, following radiation therapy. ClinicalTrials.gov. [cited 2025 Jul 16]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT02607124."},{"key":"ref218","unstructured":"Study Details. Adavosertib and local radiation therapy in treating children with newly diagnosed diffuse intrinsic pontine gliomas. ClinicalTrials.gov. [cited 2025 Jul 16]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01922076."},{"key":"ref219","unstructured":"Study Details. Erlotinib and radiation therapy in treating young patients with newly diagnosed glioma. ClinicalTrials.gov. [cited 2025 Jul 16]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00124657."},{"key":"ref220","unstructured":"Study Details. Imatinib mesylate with or without radiation therapy in treating young patients with newly diagnosed or recurrent glioma. ClinicalTrials.gov.\u201d [cited 2025 Jul 16]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00021229."},{"key":"ref221","unstructured":"Study Details. Intraarterial infusion of erbitux and bevacizumab for relapsed\/Refractory intracranial glioma in patients under 22. ClinicalTrials.gov. [cited 2025 Jul 16]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT01884740."},{"key":"ref222","unstructured":"Study Details. Lapatinib in treating young patients with recurrent or refractory central nervous system tumors. ClinicalTrials.gov. [cited 2025 Jul 16]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT00095940."},{"key":"ref223","unstructured":"Study Details. MTX110 by convection-enhanced delivery in treating participants with newly-diagnosed diffuse intrinsic pontine glioma. ClinicalTrials.gov. [cited 2025 Jul 16]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03566199."},{"key":"ref224","unstructured":"Study Details. Palbociclib isethionate in treating younger patients with recurrent, progressive, or refractory central nervous system tumors. ClinicalTrials.gov. [cited 2025 Jul 16]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT02255461."},{"key":"ref225","unstructured":"Study Details. Phase I study of APX005M in pediatric central nervous system tumors. ClinicalTrials.gov. [cited 2025 Jul 16]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT03389802?term=APX005M&viewType=Table&rank=7."},{"key":"ref226","unstructured":"Study Details. Phase I\/II study of avelumab in pediatric cancer participants. ClinicalTrials.gov. [cited 2025 Jul 16]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03451825."},{"key":"ref227","unstructured":"Study Details. Ribociclib and everolimus in treating children with recurrent or refractory malignant brain tumors. ClinicalTrials.gov. [cited 2025 Jul 16]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03387020."},{"key":"ref228","unstructured":"Study Details. Study of irinotecan and bevacizumab with temozolomide in refractory\/relapsed central nervous system (CNS) Tumors. ClinicalTrials.gov. [cited 2025 Jul 16]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT00876993."},{"key":"ref229","unstructured":"Study Details. Study of lenalidomide with vorinostat in pediatric patients with high grade or progressive CNS tumors. ClinicalTrials.gov. [cited 2025 Jul 16]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT03050450?intr=%22Lenalidomide%22&viewType=Table&rank=6."},{"key":"ref230","unstructured":"Study Details. Trial of panobinostat in children with diffuse intrinsic pontine glioma. ClinicalTrials.gov. [cited 2025 Jul 16]. Available from: https:\/\/www.clinicaltrials.gov\/study\/NCT02717455."},{"key":"ref231","unstructured":"Study Details. A study to evaluate the safety and efficacy of nivolumab monotherapy and nivolumab in combination with ipilimumab in pediatric participants with high grade primary central nervous system (CNS) Malignancies. ClinicalTrials.gov. [cited 2025 Jul 16]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03130959?term=AREA%5BExpandedAccessNCTId%5DNCT03126643&rank=7."},{"key":"ref232","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/ng.1102","article-title":"Jude Children\u2019s Research Hospital-Washington University Pediatric Cancer Genome Project. Somatic histone H3 alterations in pediatric diffuse intrinsic pontine gliomas and non-brainstem glioblastomas","volume":"44","year":"2012","journal-title":"Nat Genet"},{"key":"ref233","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1038\/nature10833","article-title":"Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma","volume":"482","author":"Schwartzentruber","year":"2012","journal-title":"Nature"},{"key":"ref234","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s00401-012-0998-0","article-title":"K27M mutation in histone H3.3 defines clinically and biologically distinct subgroups of pediatric diffuse intrinsic pontine gliomas","volume":"124","author":"Khuong-Quang","year":"2012","journal-title":"Acta Neuropathol"},{"key":"ref235","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1126\/science.1232245","article-title":"Inhibition of PRC2 activity by a gain-of-function H3 mutation found in pediatric glioblastoma","volume":"340","author":"Lewis","year":"2013","journal-title":"Science"},{"key":"ref236","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.ccr.2013.10.006","article-title":"Reduced H3K27me3 and DNA hypomethylation are major drivers of gene expression in K27M mutant pediatric high-grade gliomas","volume":"24","author":"Bender","year":"2013","journal-title":"Cancer Cell"},{"key":"ref237","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00401-020-02142-w","article-title":"Histone H3 wild-type DIPG\/DMG overexpressing EZHIP extend the spectrum diffuse midline gliomas with PRC2 inhibition beyond H3-K27M mutation","volume":"139","author":"Castel","year":"2020","journal-title":"Acta Neuropathol"},{"key":"ref238","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for subependymal giant-cell astrocytomas in tuberous sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N Engl J Med"},{"key":"ref239","doi-asserted-by":"crossref","first-page":"8673","DOI":"10.1158\/0008-5472.CAN-08-2097","volume":"68","author":"Jones","year":"2008","journal-title":"Cancer Res"},{"key":"ref240","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1172\/JCI33656","article-title":"BRAF gene duplication constitutes a mechanism of MAPK pathway activation in low-grade astrocytomas","volume":"118","author":"Pfister","year":"2008","journal-title":"J Clin Invest"},{"key":"ref241","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1038\/ng.2682","article-title":"Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma","volume":"45","author":"Jones","year":"2013","journal-title":"Nat Genet"},{"key":"ref242","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1038\/ng.3500","article-title":"MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism","volume":"48","author":"Bandopadhayay","year":"2016","journal-title":"Nat Genet"},{"key":"ref243","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ccell.2020.03.011","article-title":"Integrated molecular and clinical analysis of 1,000 pediatric low-grade gliomas","volume":"37","author":"Ryall","year":"2020","journal-title":"Cancer Cell"},{"key":"ref244","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1007\/s11060-024-04857-2","article-title":"Targeting the RAS\/MAPK pathway in children with glioma","volume":"171","author":"Cacciotti","year":"2025","journal-title":"J Neurooncol"},{"key":"ref245","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1056\/NEJMoa2303815","volume":"389","author":"Bouffet","year":"2023","journal-title":"N Engl J Med"},{"key":"ref246","article-title":"Integrated response analysis of pediatric low-grade gliomas during and after targeted therapy treatment","volume":"5","author":"Tsai","year":"2023","journal-title":"Neurooncol Adv"},{"key":"ref247","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s43018-021-00319-0","article-title":"The current landscape of immunotherapy for pediatric brain tumors","volume":"3","author":"Hwang","year":"2022","journal-title":"Nat Cancer"},{"key":"ref248","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1016\/j.cell.2023.03.006","article-title":"Immune checkpoint therapy\u2014current perspectives and future directions","volume":"186","author":"Sharma","year":"2023","journal-title":"Cell"},{"key":"ref249","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"ref250","doi-asserted-by":"crossref","first-page":"4770","DOI":"10.1158\/1078-0432.CCR-23-0411","article-title":"Efficacy of nivolumab in pediatric cancers with high mutation burden and mismatch repair deficiency","volume":"29","author":"Das","year":"2023","journal-title":"Clin Cancer Res"},{"key":"ref251","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1038\/s41591-021-01404-8","article-title":"Locoregional infusion of HER2-specific CAR T cells in children and young adults with recurrent or refractory CNS tumors: an interim analysis","volume":"27","author":"Vitanza","year":"2021","journal-title":"Nat Med"},{"key":"ref252","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1038\/s41591-023-02276-w","article-title":"Tumor inflammation-associated neurotoxicity","volume":"29","author":"Mahdi","year":"2023","journal-title":"Nat Med"},{"key":"ref253","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2307\/2531628","article-title":"Continual reassessment method: a practical design for phase 1 clinical trials in cancer","volume":"46","author":"O\u2019Quigley","year":"1990","journal-title":"Biometrics"},{"key":"ref254","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1200\/JCO.2007.12.7712","article-title":"Shortening the timeline of pediatric phase I trials: the rolling six design","volume":"26","author":"Skolnik","year":"2008","journal-title":"J Clin Oncol"}],"container-title":["Oncology Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/cdn.techscience.cn\/files\/or\/2025\/TSP_OR-33-10\/OncolRes-33-10-66260\/OncolRes-33-66260.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T02:17:26Z","timestamp":1763345846000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.techscience.com\/or\/v33n10\/63883"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":254,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025]]},"published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.32604\/or.2025.066260","relation":{},"ISSN":["1555-3906"],"issn-type":[{"value":"1555-3906","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}